Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.
Avecho resumes pivotal insomnia trial recruitment after positive interim review
August 31, 2026 Australian Biotech
Latest Video
New Stories
-
Alterity secures option underwriting as it prepares for pivotal MSA trial
August 31, 2026 - - Australian Biotech -
Avecho resumes pivotal insomnia trial recruitment after positive interim review
August 31, 2026 - - Australian Biotech -
Tetratherix sends first commercial polymer shipment to United States
August 31, 2026 - - Australian Biotech -
Expansion opens PBS access for more with advanced cancer, but it took a long time
August 31, 2026 - - Latest News -
A decade is more than enough - the case for term limits on advisory committees
August 31, 2026 - - Latest News -
September agenda puts cancer drugs, RSV prevention and ADHD access in focus
August 31, 2026 - - Latest News -
Funding brings a new targeted treatment for Australians with lupus kidney disease
August 31, 2026 - - Latest News
